

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOAL AND OBJECTIVES .....	1
REASONS FOR DOING THE STUDY .....	1
INTENDED AUDIENCE.....	2
SCOPE OF REPORT .....	2
INFORMATION SOURCES AND METHODOLOGY.....	3
AUTHOR’S CREDENTIALS .....	4
RELATED BCC REPORTS .....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER .....	5
CHAPTER TWO: SUMMARY.....	6
<i>SUMMARY TABLE GLOBAL SALES OF DRUGS FOR IMMUNE</i>	
<i>DISEASES, THROUGH 2015 (\$ MILLIONS)</i> .....	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR DRUGS TO TREAT</i>	
<i>IMMUNE DISEASES, 2009-2015 (\$ MILLIONS)</i> .....	7
CHAPTER THREE: OVERVIEW .....	8
IMMUNE SYSTEM BACKGROUND .....	8
INNATE (NATURAL) IMMUNITY.....	8
Neutrophils .....	8
Eosinophils.....	9
Basophils.....	9
Mononuclear Cells .....	9
The Complement System – An Effector Component of an	
Immune Response .....	10
ACQUIRED (ADAPTIVE) IMMUNITY .....	11
T Cells .....	11
Th Cells (CD4+ T Cells).....	12
Tc Cells (CD8+ T Cells) .....	12
B Cells .....	13
Null Cells (Natural Killer Cells).....	13
<i>TABLE 1 CELLS OF THE ADAPTIVE IMMUNE SYSTEM AND THEIR</i>	
<i>FUNCTION</i> .....	14
HOW THE BODY RECOGNIZES “SELF” .....	14
HOW THE BODY PREVENTS AUTOIMMUNE DISEASES.....	15
THE PROBLEM OF REDUNDANCY AND COMPLEXITY.....	15
TYPES OF IMMUNE DISEASES .....	16
<i>TABLE 2 CLASSIFICATION OF IMMUNE RESPONSES LEADING TO</i>	
<i>DISEASES</i> .....	16
CLASSIFICATION OF DRUGS FOR THE TREATMENT OF	
IMMUNE DISEASES .....	17
Immunomodulators .....	17
Symptom–Treating Drugs.....	18
A LOOK AT THE INDUSTRY .....	18

<i>TABLE 3</i>	<i>KEY CHALLENGES OF THE IMMUNE DISEASES MARKET.....</i>	<i>18</i>
	EXPENSIVE BIOLOGICS ARE LEADING TO GOVERNMENT REGULATIONS TO CUT DOWN HEALTHCARE EXPENSES .....	19
	INSURANCE COMPANIES PROMOTING THE USE OF GENERICS.....	19
	ADVERSE REACTIONS ARE LEADING TO INTENSE SCRUTINY OF DRUGS AND LIMIT THE REACH OF DRUGS IN THE MARKET .....	20
	IMPACT OF THE U.S. HEALTHCARE REFORM BILL .....	20
	REGULATORY RESTRICTIONS ON LONG-ACTING BETA AGONISTS (LABA) .....	21
	“ME-TOO” BIOLOGICS MAY CROWD THE MARKET AND LIMIT THE POTENTIAL FOR NEW THERAPIES .....	21
	BIOSIMILARS AND BIO-BETTERS – THREATS AND OPPORTUNITIES .....	22
	SUCCESS OF TNF-ALPHA INHIBITORS RAISE THE ENTRY BARRIERS FOR NEW TREATMENT APPROACHES .....	22
	ATTACK ON CORE PATENTS OF BLOCKBUSTER DRUGS BY AGGRESSIVE GENERIC MANUFACTURERS IS ON THE RISE.....	23
	THE IMMUNE DISEASES AND DISORDERS MARKET.....	23
<i>TABLE 4</i>	<i>GLOBAL DEMAND OF DRUGS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, THROUGH 2015 (\$ MILLIONS).....</i>	<i>24</i>
<i>TABLE 5</i>	<i>GLOBAL DEMAND FOR IMMUNOSUPPRESSANTS AND OTHER IMMUNOMODULATORS, BY VALUE, THROUGH 2015 (\$ MILLIONS).....</i>	<i>24</i>
<i>TABLE 6</i>	<i>GLOBAL MARKET SHARE OF IMMUNOSUPPRESSANTS IN THE IMMUNOMODULATORS MARKETS, 2009-2015 (%).....</i>	<i>24</i>
<i>TABLE 7</i>	<i>GLOBAL MARKET SHARE OF IMMUNOMODULATORS AND SYMPTOM-TREATING DRUGS IN IMMUNE DISEASE MARKETS, 2009-2015 (%).....</i>	<i>25</i>
<i>FIGURE 1</i>	<i>GLOBAL MARKETS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, 2009-2015 (\$ MILLIONS).....</i>	<i>25</i>
	REGIONAL MARKETS OF IMMUNE DISEASES AND DISORDERS .....	25
<i>TABLE 8</i>	<i>U.S. DEMAND OF DRUGS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, THROUGH 2015 (\$ MILLIONS).....</i>	<i>26</i>
<i>TABLE 9</i>	<i>U.S. DEMAND FOR IMMUNOMODULATORS, BY VALUE, THROUGH 2015 (\$ MILLIONS).....</i>	<i>26</i>
<i>TABLE 10</i>	<i>U.S. MARKET SHARE OF IMMUNOSUPPRESSANTS IN THE IMMUNOMODULATORS MARKETS, 2009-2015 (%).....</i>	<i>26</i>
<i>TABLE 11</i>	<i>U.S. MARKET SHARES OF IMMUNOMODULATORS AND SYMPTOM-TREATING DRUGS IN IMMUNE DISEASE MARKETS, 2009-2015 (%).....</i>	<i>27</i>

<i>FIGURE 2 U.S. MARKETS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, 2009-2015 (\$ MILLIONS)</i> .....	27
<i>TABLE 12 ROW DEMAND FOR DRUGS FOR IMMUNE DISEASES AND DISORDERS, BY VALUE, THROUGH 2015 (\$ MILLIONS)</i> .....	28
<i>TABLE 13 ROW DEMAND FOR IMMUNOMODULATORS, BY VALUE, THROUGH 2015 (\$ MILLIONS)</i> .....	28
<i>TABLE 14 ROW MARKET SHARE OF IMMUNOSUPPRESSANTS IN THE IMMUNOMODULATORS MARKETS, 2009-2015 (%)</i> .....	28
<i>TABLE 15 ROW MARKET SHARE OF IMMUNOMODULATORS AND SYMPTOM-TREATING DRUGS IN IMMUNE DISEASE MARKETS, 2009-2015 (%)</i> .....	29
<i>FIGURE 3 ROW MARKETS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, 2009-2015 (\$ MILLIONS)</i> .....	29
<i>FIGURE 4 REGIONAL MARKET SIZE OF DRUGS FOR IMMUNE DISEASES AND THEIR FUTURE GROWTH TRENDS, 2009-2015 (\$ MILLIONS)</i> .....	30
MARKET SHARE BY TECHNOLOGY TYPES .....	30
<i>TABLE 16 GLOBAL IMMUNE DISEASES AND DISORDERS MARKETS BASED ON TECHNOLOGY TYPES, BY VALUE, THROUGH 2015 (\$ MILLIONS)</i> .....	31
THE RISING MARKET SHARE OF BIOLOGICS.....	31
<i>TABLE 17 MARKET SHARE OF BIOLOGICS IN THE GLOBAL IMMUNE DISEASES MARKETS, BY VALUE, THROUGH 2015 (\$ MILLIONS)</i> .....	32
<i>TABLE 18 TOP 10 DRUGS IN THE IMMUNE DISEASE MARKETS, WORLDWIDE, 2010 (%)</i> .....	32
<i>TABLE 19 REVENUE AND MARKET SHARES OF MONOCLONAL ANTIBODIES, IMMUNE DISEASE MARKETS, THROUGH 2015 (%)</i> .....	33
TOP COMPANIES BY SALES IN THE IMMUNE DISEASE MARKETS .....	33
<i>TABLE 20 MARKET SHARES OF TOP 10 PLAYERS OF GLOBAL IMMUNE DISEASES MARKETS, 2010 (%)</i> .....	33
BIOLOGICAL RESPONSE MODIFIERS (BRMS) CONTINUES AS A STRONG SECTOR IN THE IMMUNE DISEASE MARKETS .....	34
<i>TABLE 21 MARKET SIZE OF KEY DRUGS THAT CAN BE CATEGORIZED AS BRMS IN THE IMMUNE DISEASE MARKETS, THROUGH 2015 (\$ MILLIONS)</i> .....	34
PAY-TO-DELAY GENERICS – AN EMERGING TREND? .....	34
MARKET SHARE OF COMBINATION DRUGS IS INCREASING .....	35
<i>TABLE 22 SUCCESSFUL COMBINATION DRUG BRANDS AND PIPELINE PRODUCTS IN THE IMMUNE DISEASE MARKETS</i> .....	35
<i>TABLE 23 MARKET SIZE OF COMBINATION DRUGS, THROUGH 2015 (\$ MILLIONS/%)</i> .....	36
CHAPTER FOUR: IMMUNOMODULATORS .....	37

IMMUNOSUPPRESSANTS .....	37
<i>TABLE 24 GLOBAL MARKET FOR IMMUNOSUPPRESSANTS TO TREAT IMMUNE DISEASES, THROUGH 2015 (\$ MILLIONS)</i> .....	38
CORTICOSTEROIDS .....	38
<i>TABLE 25 SALES OF CORTICOSTEROID BRANDS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	39
COMBINATION DRUGS OF CORTICOSTEROIDS WITH OTHER CLASSES .....	40
<i>TABLE 26 SALES OF TOP BRANDS OF ICS/LABA COMBINATION DRUGS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	40
LEUKOTRIENE ANTAGONISTS.....	40
<i>TABLE 27 SALES OF LEUKOTRIENE ANTAGONIST BRANDS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	41
TNF-ALPHA ANTAGONISTS.....	41
<i>TABLE 28 SALES OF KEY TNF-ALPHA ANTAGONIST BRANDS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	42
IMMUNOPHILIN BINDING DRUGS .....	43
<i>TABLE 29 SALES OF KEY IMMUNOPHILIN INHIBITOR BRANDS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	44
INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) ANTAGONISTS.....	45
<i>TABLE 30 SALES OF KEY INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) ANTAGONISTS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	45
CD20 ANTAGONISTS .....	45
<i>TABLE 31 SALES OF CD20 ANTAGONISTS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	46
B CELL-TARGETED THERAPEUTICS.....	46
ALPHA 4 INTEGRIN INHIBITOR .....	46
<i>TABLE 32 SALES OF ALPHA 4 INTEGRIN ANTAGONISTS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	47
IGE ANTAGONISTS.....	47
<i>TABLE 33 SALES OF ALPHA 4 INTEGRIN ANTAGONISTS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	48
COMPLEMENT ANTAGONISTS .....	48
<i>TABLE 34 SALES OF COMPLEMENT ANTAGONISTS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	49
MISCELLANEOUS.....	49
<i>TABLE 35 SALES OF MISCELLANEOUS IMMUNOSUPPRESSANTS AND SUPPLIERS, 2010 (\$ MILLIONS)</i> .....	49
IL-1 Antagonists .....	50
IL-2 Antagonists .....	50
IL-4 Antagonists .....	51
IL-5 Antagonists .....	51

IL-6 Antagonists .....	51
IL-12/IL-23 Antagonists.....	52
Anti-Thymocyte Globulin .....	52
<b>TABLE 36 FACTORS THAT WILL IMPACT THE FUTURE MARKET</b>	
<b>SHARE OF THYMOGLOBULIN.....</b>	<b>53</b>
CD2 Antagonists.....	53
CD3 Antagonists.....	53
CD4 Antagonists.....	54
CD54 Antagonists.....	54
CD147 Antagonists.....	55
B7 Antagonist- CTLA4 .....	55
Phosphodiesterase Type IV Antagonists .....	55
Sphingosine 1 - Phosphate Receptor Agonist .....	56
Adenosine Deaminase .....	56
Alkylating Agents.....	57
Anti-Folates.....	57
Anti-Metabolites .....	57
Antibiotic Immunosuppressants.....	58
Antimalarial Drugs .....	58
Chemokine Antagonists .....	58
Gold Compounds.....	59
P38 Kinase Antagonists .....	59
Selectin Antagonists.....	59
OTHER IMMUNOMODULATORS.....	60
<b>TABLE 37 GLOBAL MARKET FOR OTHER IMMUNOMODULATORS</b>	
<b>TO TREAT IMMUNE DISEASES, THROUGH 2015 (\$ MILLIONS).....</b>	<b>60</b>
BETA INTERFERONS .....	60
<b>TABLE 38 SALES OF BETA INTERFERONS AND SUPPLIERS, 2010 (\$</b>	
<b>MILLIONS).....</b>	<b>61</b>
DOUBLE-STRANDED DNA.....	62
IL-10.....	62
PEPTIDE FRAGMENTS .....	63
<b>TABLE 39 SALES OF PEPTIDE FRAGMENTS AS</b>	
<b>IMMUNOMODULATORS AND SUPPLIERS, 2010 (\$ MILLIONS).....</b>	<b>63</b>
<b>CHAPTER FIVE: DRUGS TO TREAT SYMPTOMS OF IMMUNE DISEASE.....</b>	<b>64</b>
DRUGS TO TREAT SYMPTOMS OF IMMUNE DISEASE.....	64
<b>TABLE 40 GLOBAL MARKET FOR SYMPTOM-TREATING DRUGS</b>	
<b>TO TREAT IMMUNE DISEASES, THROUGH 2015 (\$ MILLIONS).....</b>	<b>65</b>
H1 BLOCKERS.....	65
<b>TABLE 41 SALES OF H1 RECEPTOR BLOCKER BRANDS AND</b>	
<b>THEIR SUPPLIERS, 2010 (\$ MILLIONS) .....</b>	<b>65</b>
BETA AGONISTS .....	66
<b>TABLE 42 ALES OF KEY BETA AGONIST BRANDS AND THEIR</b>	
<b>SUPPLIERS, 2010 (\$ MILLIONS).....</b>	<b>67</b>

NSAIDS (COX INHIBITORS) .....	67
NITRIC OXIDE-RELEASING NSAIDS .....	68
<i>TABLE 43 SALES OF KEY NSAID BRANDS AND THEIR SUPPLIERS,</i> <i>2010 (\$ MILLIONS).....</i>	<i>68</i>
OTHER SYMPTOM-TREATING DRUGS IN THE IMMUNE DISEASE MARKETS .....	69
<i>TABLE 44 SALES OF OTHER CLASSES OF SYMPTOM-TREATING</i> <i>DRUG BRANDS AND THEIR SUPPLIERS, 2010 (\$ MILLIONS) .....</i>	<i>69</i>
SYNTHETIC THYROID HORMONE .....	69
AMINOSALICYLATES.....	70
RETINOIDS .....	70
THROMBOXANE A2 ANTAGONISTS.....	70
VITAMIN D DERIVATIVES .....	71
MUSCARINIC BLOCKERS.....	71
CHOLINESTERASE INHIBITORS .....	71
 CHAPTER SIX: TECHNOLOGY TRENDS AND PATENT ANALYSIS .....	 72
<i>TABLE 45 NUMBER OF HITS RECEIVED IN THE DATABASE</i> <i>SEARCH FOR PATENT APPLICATIONS FILED WITH U.S. PTO</i> <i>FOR VARIOUS TECHNOLOGY AREAS, 2001-2010 .....</i>	   <i>72</i>
<i>TABLE 45 (CONTINUED).....</i>	<i>73</i>
<i>TABLE 46 NUMBER OF HITS RECEIVED IN THE PATENTS</i> <i>DATABASE OF U.S. PTO BETWEEN 2001 AND 2010 FOR</i> <i>SELECTED MOLECULES .....</i>	   <i>74</i>
<i>TABLE 47 PROMISING DRUGS FOR THE TREATMENT OF IMMUNE</i> <i>DISEASES LAUNCHED RECENTLY/ADVANCED STAGES OF</i> <i>DEVELOPMENT.....</i>	   <i>75</i>
FIRST ORAL PDE-IV INHIBITOR ENTERS THE MARKET .....	75
THE SCOPE OF IL-12/IL-23 INHIBITORS FOR PSORIASIS.....	76
<i>TABLE 48 DRIVERS AND RESTRAINTS OF IL-12/IL-23 INHIBITORS</i> <i>AS A NEW CLASS OF DRUGS FOR IMMUNE DISEASES .....</i>	   <i>77</i>
JAK3 ANTAGONISTS AS HIGHLY SELECTIVE IMMUNOSUPPRESSANTS.....	 77
S1PR1 INHIBITORS .....	78
<i>TABLE 49 DRIVERS AND RESTRAINTS OF S1PR1 INHIBITORS AS A</i> <i>NEW CLASS OF DRUGS FOR IMMUNE DISEASES .....</i>	   <i>78</i>
 CHAPTER SEVEN: COMMON IMMUNE DISEASES AND THEIR THERAPIES .....	  79
<i>TABLE 50 PREVALENCE OF COMMON IMMUNE DISEASES .....</i>	<i>79</i>
<i>TABLE 51 GLOBAL MARKET SIZE OF VARIOUS CATEGORIES OF</i> <i>IMMUNE DISEASES, THROUGH 2015 (\$ MILLIONS).....</i>	   <i>80</i>
RESPIRATORY DISEASES .....	80
ASTHMA.....	80
Asthma (Continued) .....	81

ALLERGIC RHINITIS .....	82
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) .....	82
MARKET SCENARIO OF THE TREATMENT FOR RESPIRATORY DISEASES .....	83
<i>TABLE 52 COMMON BRANDS USED FOR THE TREATMENT OF ASTHMA, ALLERGIC RHINITIS AND COPD .....</i>	<i>84</i>
<i>TABLE 53 SALES OF KEY BRANDS USED FOR THE TREATMENT OF RESPIRATORY DISEASES IN 2010 AND THEIR SUPPLIERS (\$ MILLIONS) .....</i>	<i>85</i>
<i>TABLE 54 GLOBAL MARKET FOR IMMUNOMODULATORS AND SYMPTOM –TREATING DRUGS TO TREAT RESPIRATORY DISEASES, THROUGH 2015 (\$ MILLIONS).....</i>	<i>85</i>
RHEUMATOID ARTHRITIS (RA).....	86
RHEUMATOID ARTHRITIS (RA) (CONTINUED) .....	87
RHEUMATOID ARTHRITIS (RA) (CONTINUED) .....	88
RHEUMATOID ARTHRITIS (RA) (CONTINUED) .....	89
<i>TABLE 55 COMMON BRANDS USED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS .....</i>	<i>90</i>
PSORIASIS/PSORIATIC ARTHRITIS .....	90
PSORIASIS/PSORIATIC ARTHRITIS (CONTINUED).....	91
<i>TABLE 56 DRIVERS AND RESTRAINTS FOR STELARA IN PSORIASIS MARKET.....</i>	<i>92</i>
<i>TABLES 57 KEY BRANDS USED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS, PSORIASIS, AND PSORIATIC ARTHRITIS AND THEIR SUPPLIERS.....</i>	<i>93</i>
<i>TABLE 58 GLOBAL MARKET FOR IMMUNOMODULATORS AND SYMPTOM –TREATING DRUGS TO TREAT AUTOIMMUNE DISEASES AFFECTING JOINTS AND SKIN*, THROUGH 2015 (\$ MILLIONS).....</i>	<i>94</i>
CROHN'S DISEASE AND ULCERATIVE COLITIS (INFLAMMATORY BOWEL DISEASES).....	94
CROHN'S DISEASE AND ULCERATIVE ... (CONTINUED) .....	95
<i>TABLES 59 KEY BRANDS USED FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND THEIR SUPPLIERS.....</i>	<i>96</i>
<i>TABLE 60 GLOBAL MARKET FOR IMMUNOMODULATORS AND SYMPTOM –TREATING DRUG BRANDS TO TREAT INFLAMMATORY BOWEL DISEASES*, THROUGH 2015 (\$ MILLIONS).....</i>	<i>96</i>
MULTIPLE SCLEROSIS .....	97
MULTIPLE SCLEROSIS (CONTINUED) .....	98
<i>TABLE 61 KEY BRANDS USED FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR SUPPLIERS .....</i>	<i>99</i>
<i>TABLE 62 COMPARISON OF MAJOR DRUGS IN THE MS MARKET, 2010 (\$ MILLIONS).....</i>	<i>99</i>

<i>TABLE 62 (CONTINUED)</i> .....	100
<i>TABLE 63 GLOBAL MARKET FOR IMMUNOMODULATORS TO TREAT MULTIPLE SCLEROSIS, THROUGH 2015 (\$ MILLIONS)</i> .....	101
TRANSPLANT REJECTION AND GRAFT VS. HOST DISEASE (GVHD).....	101
<i>TABLE 64 KEY IMMUNOMODULATOR BRANDS IN THE TRANSPLANT REJECTION MARKETS*</i> .....	102
<i>TABLE 65 GLOBAL MARKET FOR IMMUNOMODULATORS FOR TRANSPLANT REJECTION AND GRAFT VS. HOST DISEASE, THROUGH 2015 (\$ MILLIONS)</i> .....	103
<i>TABLE 66 NOVEL IMMUNOSUPPRESSANTS UNDER DEVELOPMENT FOR TRANSPLANT REJECTION AND GVHD</i> .....	104
INNOVATIVE APPROACHES IN TRANSPLANTATION MARKETS– BUT IS THE MARKET READY? .....	105
SYSTEMIC LUPUS ERYTHEMATOSUS .....	106
SYSTEMIC LUPUS ERYTHEMATOSUS (CONTINUED).....	107
MYASTHENIA GRAVIS.....	108
HASHIMOTO’S THYROIDITIS.....	109
<i>TABLE 67 GLOBAL MARKET FOR THE DRUGS USED FOR THE TREATMENT OF HASHIMOTO’S DISEASE, THROUGH 2015 (\$ MILLIONS)</i> .....	109
SCLERODERMA .....	110
ANKYLOSING SPONDILITIS.....	111
<i>TABLE 68 GLOBAL MARKET FOR THE DRUGS USED FOR THE TREATMENT OF ANKYLOSING SPONYLITIS, THROUGH 2015 (\$ MILLIONS)</i> .....	112
 CHAPTER EIGHT: COMPANY PROFILES .....	 113
ABBOTT LABORATORIES.....	113
ALEXION PHARMACEUTICALS, INC. ....	113
AMGEN, INC. ....	114
APT PHARMACEUTICALS, INC. ....	115
ASTELLAS PHARMA.....	116
ASTRA ZENECA PLC .....	116
ATLANTIC HEALTHCARE LTD. ....	117
BAYER SCHERING PHARMA AG.....	118
BIOGEN IDEC, INC.....	118
BRISTOL–MYERS SQUIBB .....	119
BOEHRINGER INGELHEIM GMBH .....	120
CELLDEX THERAPEUTICS, INC. ....	121
CEPHALON, INC. ....	122
F. HOFFMANN–LA ROCHE, LTD.....	122
GENZYME CORPORATION.....	123
GLAXO SMITHKLINE PLC .....	124
JOHNSON & JOHNSON .....	125



MERCK & CO, INC. ....	126
NOVARTIS INTERNATIONAL AG.....	127
OSIRIS THERAPEUTICS, INC. ....	128
PFIZER, INC. ....	129
PFIZER, INC. (CONTINUED).....	130
PFIZER, INC. (CONTINUED).....	131
GLOSSARY .....	132
GLOSSARY .....	132
GLOSSARY (CONTINUED).....	133